קלופידקסל 75

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

CLOPIDOGREL AS BESYLATE 75 MG

Disponible desde:

DEXCEL PHARMA TECHNOLOGIES LTD

Código ATC:

B01AC04

formulario farmacéutico:

FILM COATED TABLETS

Vía de administración:

PER OS

Fabricado por:

PHARMATHEN S.A., GREECE

Grupo terapéutico:

CLOPIDOGREL

indicaciones terapéuticas:

Clopidogrel is indicated for the prevention of atherothrombotic events as follows:• Recent MI, Recent stroke or Established peripheral arterial disease: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For patients with a history of recent myocardial infarction (MI), recent stroke or established peripheral arterial disease, Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not) and other vascular death.• Acute coronary syndrome: For patients with acute coronary syndrome (Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST segment elevation acute myocardial infarction), in combination with ASA in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG clopi

Fecha de autorización:

2010-09-01